Additionally, although the immunity benefits of IFN-III have been revealed, it is not yet clear whether the IFN-III/TSLP axis functions in defeating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the context of coronavirus disease 2019 (COVID-19) pandemic (130–135). The gene discussed is TSLP; the disease is COVID-19.